Skip to main content
Erschienen in: Journal of Neuro-Oncology 2/2019

19.01.2019 | Clinical Study

Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas

verfasst von: Hao Zhou, Ken Chang, Harrison X. Bai, Bo Xiao, Chang Su, Wenya Linda Bi, Paul J. Zhang, Joeky T. Senders, Martin Vallières, Vasileios K. Kavouridis, Alessandro Boaro, Omar Arnaout, Li Yang, Raymond Y. Huang

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Isocitrate dehydrogenase (IDH) and 1p19q codeletion status are importantin providing prognostic information as well as prediction of treatment response in gliomas. Accurate determination of the IDH mutation status and 1p19q co-deletion prior to surgery may complement invasive tissue sampling and guide treatment decisions.

Methods

Preoperative MRIs of 538 glioma patients from three institutions were used as a training cohort. Histogram, shape, and texture features were extracted from preoperative MRIs of T1 contrast enhanced and T2-FLAIR sequences. The extracted features were then integrated with age using a random forest algorithm to generate a model predictive of IDH mutation status and 1p19q codeletion. The model was then validated using MRIs from glioma patients in the Cancer Imaging Archive.

Results

Our model predictive of IDH achieved an area under the receiver operating characteristic curve (AUC) of 0.921 in the training cohort and 0.919 in the validation cohort. Age offered the highest predictive value, followed by shape features. Based on the top 15 features, the AUC was 0.917 and 0.916 for the training and validation cohort, respectively. The overall accuracy for 3 group prediction (IDH-wild type, IDH-mutant and 1p19q co-deletion, IDH-mutant and 1p19q non-codeletion) was 78.2% (155 correctly predicted out of 198).

Conclusion

Using machine-learning algorithms, high accuracy was achieved in the prediction of IDH genotype in gliomas and moderate accuracy in a three-group prediction including IDH genotype and 1p19q codeletion.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
3.
Zurück zum Zitat Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31(4):431–436CrossRefPubMed Recht LD, Lew R, Smith TW (1992) Suspected low-grade glioma: is deferring treatment safe? Ann Neurol 31(4):431–436CrossRefPubMed
5.
6.
Zurück zum Zitat Hartmann C et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718CrossRefPubMed Hartmann C et al (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718CrossRefPubMed
7.
Zurück zum Zitat Houillier C et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75(17):1560–1566CrossRefPubMed Houillier C et al (2010) IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas. Neurology 75(17):1560–1566CrossRefPubMed
8.
Zurück zum Zitat Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed Louis DN et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
9.
Zurück zum Zitat Weller M et al (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379CrossRefPubMed Weller M et al (2013) Molecular neuro-oncology in clinical practice: a new horizon. Lancet Oncol 14(9):e370–e379CrossRefPubMed
10.
Zurück zum Zitat SongTao Q et al (2012) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103(2):269–273CrossRefPubMed SongTao Q et al (2012) IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103(2):269–273CrossRefPubMed
11.
Zurück zum Zitat Molenaar RJ et al (2015) Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res 75(22):4790–4802CrossRefPubMed Molenaar RJ et al (2015) Radioprotection of IDH1-mutated cancer cells by the IDH1-mutant inhibitor AGI-5198. Cancer Res 75(22):4790–4802CrossRefPubMed
12.
Zurück zum Zitat Mohrenz IV et al (2013) Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18(11):1416–1425CrossRefPubMed Mohrenz IV et al (2013) Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death. Apoptosis 18(11):1416–1425CrossRefPubMed
13.
Zurück zum Zitat Lowery MA et al (2017) Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 35(15_suppl):4015–4015CrossRef Lowery MA et al (2017) Phase I study of AG-120, an IDH1 mutant enzyme inhibitor: results from the cholangiocarcinoma dose escalation and expansion cohorts. J Clin Oncol 35(15_suppl):4015–4015CrossRef
14.
Zurück zum Zitat Mellinghoff IK et al. (2016) ACTR-46. AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: results from the phase 1 glioma expansion cohorts. Oxford University Press, Oxford Mellinghoff IK et al. (2016) ACTR-46. AG120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: results from the phase 1 glioma expansion cohorts. Oxford University Press, Oxford
15.
Zurück zum Zitat Erdem-Eraslan L et al (2013) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 31(3):328CrossRefPubMed Erdem-Eraslan L et al (2013) Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. J Clin Oncol 31(3):328CrossRefPubMed
16.
Zurück zum Zitat Cairncross G et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337CrossRefPubMed Cairncross G et al (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31(3):337CrossRefPubMed
18.
Zurück zum Zitat Brat DJ et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498CrossRefPubMed Brat DJ et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498CrossRefPubMed
19.
Zurück zum Zitat Kickingereder P et al (2015) IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 5:16238CrossRefPubMedPubMedCentral Kickingereder P et al (2015) IDH mutation status is associated with a distinct hypoxia/angiogenesis transcriptome signature which is non-invasively predictable with rCBV imaging in human glioma. Sci Rep 5:16238CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Biller A et al (2016) Improved brain tumor classification by sodium MR imaging: prediction of IDH mutation status and tumor progression. AJNR Am J Neuroradiol 37(1):66–73CrossRefPubMedPubMedCentral Biller A et al (2016) Improved brain tumor classification by sodium MR imaging: prediction of IDH mutation status and tumor progression. AJNR Am J Neuroradiol 37(1):66–73CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Pope WB et al (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107(1):197–205CrossRefPubMed Pope WB et al (2012) Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol 107(1):197–205CrossRefPubMed
22.
Zurück zum Zitat Andronesi OC et al (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4(116):116ra4CrossRefPubMedPubMedCentral Andronesi OC et al (2012) Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med 4(116):116ra4CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Choi C et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629CrossRefPubMedPubMedCentral Choi C et al (2012) 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas. Nat Med 18(4):624–629CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Stadlbauer A et al (2017) MR imaging-derived oxygen metabolism and neovascularization characterization for grading and IDH gene mutation detection of gliomas. Radiology 283(3):799–809CrossRefPubMed Stadlbauer A et al (2017) MR imaging-derived oxygen metabolism and neovascularization characterization for grading and IDH gene mutation detection of gliomas. Radiology 283(3):799–809CrossRefPubMed
25.
Zurück zum Zitat Iwadate Y et al (2016) Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. J Neurol Neurosurg Psychiatry 87:1016–1021CrossRefPubMed Iwadate Y et al (2016) Molecular imaging of 1p/19q deletion in oligodendroglial tumours with 11C-methionine positron emission tomography. J Neurol Neurosurg Psychiatry 87:1016–1021CrossRefPubMed
26.
Zurück zum Zitat Fellah S et al (2013) Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am J Neuroradiol 34(7):1326–1333CrossRefPubMedPubMedCentral Fellah S et al (2013) Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? Am J Neuroradiol 34(7):1326–1333CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Jansen NL et al (2012) Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F] FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncology 14(12):1473–1480CrossRefPubMedPubMedCentral Jansen NL et al (2012) Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [18F] FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncology 14(12):1473–1480CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Clark K et al (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26(6):1045–1057CrossRefPubMedPubMedCentral Clark K et al (2013) The Cancer Imaging Archive (TCIA): maintaining and operating a public information repository. J Digit Imaging 26(6):1045–1057CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Chang K et al (2016) Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol 18(12):1680–1687CrossRefPubMedPubMedCentral Chang K et al (2016) Multimodal imaging patterns predict survival in recurrent glioblastoma patients treated with bevacizumab. Neuro Oncol 18(12):1680–1687CrossRefPubMedPubMedCentral
31.
32.
Zurück zum Zitat Iglesias JE et al (2011) Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging 30(9):1617–1634CrossRefPubMed Iglesias JE et al (2011) Robust brain extraction across datasets and comparison with publicly available methods. IEEE Trans Med Imaging 30(9):1617–1634CrossRefPubMed
34.
Zurück zum Zitat James G et al. (2013) An introduction to statistical learning, vol 112. Springer, New YorkCrossRef James G et al. (2013) An introduction to statistical learning, vol 112. Springer, New YorkCrossRef
35.
Zurück zum Zitat Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148(3):839–843CrossRefPubMed Hanley JA, McNeil BJ (1983) A method of comparing the areas under receiver operating characteristic curves derived from the same cases. Radiology 148(3):839–843CrossRefPubMed
36.
Zurück zum Zitat Eoli M et al (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119(1):84–90CrossRefPubMed Eoli M et al (2006) Reclassification of oligoastrocytomas by loss of heterozygosity studies. Int J Cancer 119(1):84–90CrossRefPubMed
37.
Zurück zum Zitat Megyesi JF et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10(13):4303–4306CrossRefPubMed Megyesi JF et al (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10(13):4303–4306CrossRefPubMed
38.
Zurück zum Zitat Jenkinson MD et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129(Pt 7):1884–1891CrossRefPubMed Jenkinson MD et al (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129(Pt 7):1884–1891CrossRefPubMed
39.
Zurück zum Zitat Brown R et al (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14(8):2357–2362CrossRefPubMed Brown R et al (2008) The use of magnetic resonance imaging to noninvasively detect genetic signatures in oligodendroglioma. Clin Cancer Res 14(8):2357–2362CrossRefPubMed
40.
Zurück zum Zitat Liu C et al (2012) Towards MIB-1 and p53 detection in glioma magnetic resonance image: a novel computational image analysis method. Phys Med Biol 57(24):8393–8404CrossRefPubMed Liu C et al (2012) Towards MIB-1 and p53 detection in glioma magnetic resonance image: a novel computational image analysis method. Phys Med Biol 57(24):8393–8404CrossRefPubMed
41.
Zurück zum Zitat Metellus P et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729CrossRefPubMed Metellus P et al (2010) Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol 120(6):719–729CrossRefPubMed
42.
Zurück zum Zitat Qi S et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7(6):1895–1902CrossRefPubMedPubMedCentral Qi S et al (2014) Isocitrate dehydrogenase mutation is associated with tumor location and magnetic resonance imaging characteristics in astrocytic neoplasms. Oncol Lett 7(6):1895–1902CrossRefPubMedPubMedCentral
43.
Zurück zum Zitat Park Y et al (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. Am J Neuroradiol 39(1):37–42CrossRefPubMedPubMedCentral Park Y et al (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. Am J Neuroradiol 39(1):37–42CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Zhang B et al (2017) Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 19(1):109–117CrossRefPubMed Zhang B et al (2017) Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro Oncol 19(1):109–117CrossRefPubMed
45.
Zurück zum Zitat Yu J et al (2017) Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol 27(8):3509–3522CrossRefPubMed Yu J et al (2017) Noninvasive IDH1 mutation estimation based on a quantitative radiomics approach for grade II glioma. Eur Radiol 27(8):3509–3522CrossRefPubMed
47.
Zurück zum Zitat Akkus Z et al (2017) Predicting deletion of chromosomal arms 1p/19q in low-grade gliomas from MR images using machine intelligence. J Digit Imaging 30(4):469–476CrossRefPubMedPubMedCentral Akkus Z et al (2017) Predicting deletion of chromosomal arms 1p/19q in low-grade gliomas from MR images using machine intelligence. J Digit Imaging 30(4):469–476CrossRefPubMedPubMedCentral
49.
Zurück zum Zitat Fernández-Delgado M et al (2014) Do we need hundreds of classifiers to solve real world classification problems? J Mach Learn Res 15(1):3133–3181 Fernández-Delgado M et al (2014) Do we need hundreds of classifiers to solve real world classification problems? J Mach Learn Res 15(1):3133–3181
Metadaten
Titel
Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas
verfasst von
Hao Zhou
Ken Chang
Harrison X. Bai
Bo Xiao
Chang Su
Wenya Linda Bi
Paul J. Zhang
Joeky T. Senders
Martin Vallières
Vasileios K. Kavouridis
Alessandro Boaro
Omar Arnaout
Li Yang
Raymond Y. Huang
Publikationsdatum
19.01.2019
Verlag
Springer US
Erschienen in
Journal of Neuro-Oncology / Ausgabe 2/2019
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI
https://doi.org/10.1007/s11060-019-03096-0

Weitere Artikel der Ausgabe 2/2019

Journal of Neuro-Oncology 2/2019 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.